By Dr Derek Jellinek
18 February 2021, 4:30 PM
In CSL Ltd's 1H21 results, Seqirus was the standout on pandemic driven demand for influenza vaccines, while Behring gained from Albumin sales and cost-outs, but Ig growth was modest and Specialty /Haemophilia fairly flat.
Read more...
By Dr Derek Jellinek
10 February 2021, 9:00 AM
We highlight our expectations for the following ahead of Reporting Season First Half 2021: ResMed, Sonic Healthcare, Virtus Health, Monash IVF, Volpara, Pro Medicus, and Mach7 Technologies. Watch now.
Read more...
By Scott Power
07 January 2021, 4:50 PM
In my latest network delivery, I run through a number of key themes that have our interest in the Healthcare space for 2021. I also touch on a number of upcoming catalysts.
Read more...
By Iain Wilkie
17 November 2020, 11:00 AM
Morgans analyst Iain Wilkie chats to Dr Sean Hall who is the CEO and MD of drug development company Medlab Clinical (ASX:MDC) on some recent news and upcoming catalysts.
Read more...
By Scott Power
27 October 2020, 12:05 PM
Short-term trading opportunities in the Healthcare sector
Read more...
By Dr Derek Jellinek
29 October 2020, 12:00 AM
In this note, we assess the impact across key healthcare segments, highlighting ASX and international listed companies as well as ETFs which allow exposure to these themes.
Read more...
By Dr Derek Jellinek
13 October 2020, 4:45 PM
Morgans Senior Analyst, Dr. Derek Jellinek, provides a comprehensive update on the Covid-19 Vaccine. Additionally, Derek breaks down the key stakeholders within the race, and how they are currently positioned.
Read more...
By Dr Derek Jellinek
20 August 2020, 4:00 PM
We adjust FY21-22 estimates and roll forward our valuation multiples, with our price target increasing.
Read more...
By Dr Derek Jellinek
19 August 2020, 11:00 AM
FY20 results were negatively impacted by COVID-19 deferral of elective surgeries, with sales declining across all divisions, margins contracting, underlying profit falling by double-digits and the dividend remaining suspended. As a result, we have asjusted our FY21-22 expectations.
Read more...
By Dr Derek Jellinek
27 July 2020, 10:30 AM
Morgans Senior Analysts Derek Jellinek and Scott Power share a preview of the healthcare sector ahead of the August 2020 reporting season.
Read more...